DelNova: Addressing complications from Botox (217)

Episode 17 May 24, 2022 00:19:03
DelNova: Addressing complications from Botox (217)
Innovation4Alpha
DelNova: Addressing complications from Botox (217)

May 24 2022 | 00:19:03

/

Show Notes

DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications. 

Other Episodes

Episode 15

July 28, 2021 00:28:15
Episode Cover

Featured Startup: AvodahMed (015)

AvodahMed is an advanced technology company improving quality care for patients and healthcare providers. They provide a unique solution that embeds AI throughout live...

Listen

Episode 16

August 04, 2021 00:35:31
Episode Cover

Featured Family Office: Nottingham Spirk / Katherine Hill Ritchie (016)

Katherine Hill Ritchie has extensive background running single family offices including a strong emphasis on sourcing alternative investments. Her most recent role involves both...

Listen

Episode 19

August 25, 2021 00:25:51
Episode Cover

Featured Startup: iVizz (019)

iVizz, is a Bay Area technology company which enables hospitals to prevent in-patient infections outbreaks.https://www.angelmd.co/en/startups/ivizz

Listen